LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
// Yuzo Nagai 1, 2 , Eiji Sunami 1 , Yoko Yamamoto 1 , Keisuke Hata 1 , Satoshi Okada 1 , Koji Murono 1 , Koji Yasuda 1 , Kensuke Otani 1 , Takeshi Nishikawa 1 , Toshiaki Tanaka 1 , Tomomichi Kiyomatsu 1 , Kazushige Kawai 1 , Hiroaki Nozawa 1 , Soichiro Ishihara 1 , Dave S.B. Hoon 2 , Toshiaki Watanabe 1 1 Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan 2 Department of Translational Molecular Medicine, Div. Molecular Oncology, John Wayne Cancer Institute, Saint John’s Hospital and Health Center, Santa Monica, CA, USA Correspondence to: Toshiaki Watanabe, email: toshwatanabe@yahoo.co.jp Keywords: colorectal cancer, cell-free DNA, LINE-1, hypomethylation, plasma Received: October 12, 2016 Accepted: December 20, 2016 Published: January 02, 2017 ABSTRACT Colorectal cancer (CRC) is a serious public health problem and non-invasive biomarkers improving diagnosis or therapy are strongly required. Circulating cell-free DNA (cfDNA) has been a promising target for this purpose. In this study, we evaluated the potential of long interspersed nuclear element-1 (LINE-1) hypomethylation as a blood biomarker for CRC. LINE-1 hypomethylation level in plasma cfDNA in 114 CRC patients was retrospectively examined by absolute quantitative analysis of methylated alleles real-time PCR, and was expressed using LINE-1 hypomethylation index (LHI) [unmethylated copy number/ (methylated copy number + unmethylated copy number)]. Greater LHI values indicated enhanced hypomethylation. In our clinicopathological analysis, CRC patients with large tumors (≥6.0 cm), advanced N stage (≥2), and distant metastasis (M1) had statistically significantly higher cfDNA LHI than other CRC patients, suggesting cfDNA LHI as a disease progression biomarker for CRC. Furthermore, early stage I/II (n = 57) as well as advanced stage III/IV (n =57) CRC patients had significantly higher cfDNA LHI than healthy donors (n=53) [stage I/II: median 0.369 (95% confidence interval, 0.360–0.380) vs. 0.332 (0.325–0.339), P < 0.0001; stage III/IV: 0.372 (0.365–0.388) vs. 0.332 (0.325–0.339), P < 0.0001]. The receiver operating characteristic analysis showed that cfDNA LHI had the detection capacity of CRC with area under the curve(AUC) of 0.79 and 0.83 in stage I/II and stage III/IV CRC patients, respectively. The present study demonstrated for the first time the potential of plasma cfDNA LHI as a novel biomarker for CRC, particularly for early stage detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multitarget Stool DNA Testing for Colorectal-Cancer Screening
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., Ahlquist, D. A., & Berger, B. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311194 · Cited by 1,900 · cited 1×
“Furthermore, recent fecal immunochemical test (FIT) has shown high CRC detectability [24], while the utility of stool-based DNA assays has been reported as a new application for CRC diagnosis [25].”
Method
Cited by
Epigenetics of colorectal cancer: biomarker and therapeutic potential
Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813
The epigenetic alterations of endogenous retroelements in aging
Cardelli, M. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2018.02.002 · Cited by 91
Porcellini, E., Laprovitera, N., Riefolo, M., Ravaioli, M., Garajova, I., & Ferracin, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.049 · Cited by 66
Methylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
Metadata
- Authors
- Nagai, Y., Sunami, E., Yamamoto, Y., Hata, K., Okada, S., Murono, K., Yasuda, K., Otani, K., Nishikawa, T., Tanaka, T., Kiyomatsu, T., Kawai, K., Nozawa, H., Ishihara, S., Hoon, D. S. B., & Watanabe, T.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-01-02
- Volume
- 8
- Issue
- 7
- Pages
- 11906-11916
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2563137730
- Cited by
- 79
- References
- 1
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.